Teniposide

Manufactured by Santa Cruz Biotechnology

Teniposide is a laboratory reagent used in biomedical research. It is a topoisomerase II inhibitor, which means it interferes with the enzyme topoisomerase II, which is involved in DNA replication and transcription. Teniposide can be used to study the role of topoisomerase II in various cellular processes.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using teniposide

Comprehensive Chemotherapeutic Reagent Procurement

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following reagents were purchased from Sigma: MG-132, chlorambucil, cyclophosphamide, carmustine, busulfan, dacarbazine, thiotepa, cisplatin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, methotrexate, doxorubicin, epirubicin, actinomycin-D, mitomycin-C, topotecan, irinotecan, etoposide, mitoxantrone, paclitaxel, docetaxel, and vincristine. The following reagents were purchased from Calbiochem: carboplatin, pentostatin, and daunorubicin. The following reagents were purchased from Santa Cruz: ICRF-187, ICRF-193, and teniposide. The following reagents were purchased from MBL International Corporation: Z-VAD-FMK.

Hsu J.M., Xia W., Hsu Y.H., Chan L.C., Yu W.H., Cha J.H., Chen C.T., Liao H.W., Kuo C.W., Khoo K.H., Hsu J.L., Li C.W., Lim S.O., Chang S.S., Chen Y.C., Ren G.X, & Hung M.C. (2018). STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nature Communications, 9, 1908.

+ Open protocol

+ Expand

Screening of Chemical Libraries

Check if the same lab product or an alternative is used in the 5 most similar protocols

Approximately 2000 compounds were screened from two different chemical libraries, including the Prestwick Chemical Library®, a collection of 1200 compounds at least in Phase II of clinical trials, and the BIOMOL’s FDA Approved Drug Library (Enzo Life Sciences), which consists of a collection of 640 FDA-approved drugs selected to maximize the chemical and pharmacological diversity. The compounds were supplied in 96-well plates as 10 mM (Prestwick®) and 2 mg/ml (BIOLMOL®) DMSO solutions. 5FU, DXR, daunorubicin quinacrine and methylene blue were purchased from Sigma-Aldrich and resuspended in DMSO. Epirubicin, idarubicin, pirarubicin, etoposide and teniposide were purchased from Santa Cruz, and valrubicin from Chemos.

Voisset C., Daskalogianni C., Contesse M.A., Mazars A., Arbach H., Le Cann M., Soubigou F., Apcher S., Fåhraeus R, & Blondel M. (2014). A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus. Disease Models & Mechanisms, 7(4), 435-444.

+ Open protocol

+ Expand

Validating IDH Mutant Compound Screens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Drug screening was done using IDH inhibitors AGI-5198 (Agios) or BAY-1436032 (Bayer) or the FDA-approved Oncology Drug Set II library (National Cancer Institute) containing 107 compounds. The compounds Gemcitabine hydrochloride (Sigma-Aldrich), Paclitaxel (Sigma-Aldrich), Teniposide (Santa Cruz Biotechnology, Inc), Daunorubicin hydrochloride (SelleckChem), Romidepsin (MedChemExpress), Dactinomycin (BioViotica), Regorafenib (MedChemExpress), Omacetaxine mepesuccinate (Sigma-Aldrich), and Marizomib (Sigma-Aldrich), were selected for the validation studies. Initial NIH compound screens were carried out in a 96-well format on 7 IDH mutant cultures and validation studies were performed in 384-well plates on all 12 IDH mutant cultures using the STARlet automated pipetting system (Hamilton). Serial dilutions of the selected compounds were added after 24 hours and viability was assessed by CellTiter GLO 2.0 after five days. For details see Supplementary Methods.

Verheul C., Ntafoulis I., Kers T.V., Hoogstrate Y., Mastroberardino P.G., Barnhoorn S., Payán-Gómez C., Tching Chi Yen R., Struys E.A., Koolen S.L., Dirven C.M., Leenstra S., French P.J, & Lamfers M.L. (2021). Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. Neuro-oncology Advances, 3(1), vdab103.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!